Genscript Biotech Corporation
Research Genscript Biotech Corporation (G51) on Bullrun: market cap EUR 5.86B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerG51
- ExchangeF
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 5.86B
- Financial periodFY2025
- RevenueUSD 959.53M
- Revenue growth61.4%
- Net income-USD 532.83M
- Free cash flowUSD 241.69M
- Gross margin57.7%
Valuation Snapshot
latest market cap is EUR 5.86B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 959.53M | -USD 532.83M | USD 241.69M | 57.7% | -0.25 | USD 142.49M | USD 258.84M | USD 3.96B |
| FY2024 | USD 594.49M | USD 2.96B | -USD 72.27M | 45.8% | 1.36 | USD 131.99M | USD 170.57M | USD 4.32B |
| FY2023 | USD 560.48M | -USD 95.48M | -USD 444.62M | 48.3% | -0.05 | USD 1.45B | USD 416.99M | USD 1.39B |
| FY2022 | USD 625.70M | -USD 226.85M | -USD 323.86M | 48.6% | -0.11 | USD 1.02B | USD 349.80M | USD 1.01B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 5.86B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genscript Biotech Corporation's market cap?
Genscript Biotech Corporation's market capitalization is EUR 5.86B.
What does Genscript Biotech Corporation do?
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application.